CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.
An exciting industry consisting of companies who develop new drugs to combat such diseases as cancer and other life-threatening diseases. Some may also participate in gene therapy. These firms either bring new drugs to the market themselves (which is a grueling process) or they sell their technology to bigger pharmaceutical companies.
|
| Totals |
Company |
Industry |
| Sales: |
N/A |
$86,114.6 Mil |
| Market Cap: |
$20.2 Mil |
$486,078.3 Mil |
| Analysts Recommendation: |
Strong Buy |
Buy |
|
|
| Averages |
Company |
Industry |
 |
| Growth |
| Historic Revenue: |
N/A |
54.4% |
| Estimated Revenue: |
N/A |
5.5% |
| Historic Earnings: |
N/A |
13.0% |
| Estimated Earnings: |
N/A |
7.7% |
| Stock Price (1 Year): |
(61.8%) |
19.2% |
| Cash per Share: |
N/A |
144.2% |
| Dividend: |
N/A |
N/A |
| Price |
| Trailing PE: |
N/A |
N/A |
| Forward PE: |
N/A |
40.1 |
| Price-to-Sales: |
N/A |
N/A |
| Price-to-Book: |
N/A |
5.7 |
| Dividend Yield: |
N/A |
N/A |
| Market Cap: |
$20.2 Mil |
$10,801.7 Mil |
| Operations |
| Net Margin: |
N/A |
(624.2%) |
| Gross Margin: |
N/A |
83.4% |
| Return on Equity: |
N/A |
.2 |
| Return on Assets: |
N/A |
(.0) |
| Balance Sheet |
| Current Ratio: |
N/A |
3.1 |
| Quick Ratio: |
N/A |
2.7 |
| Cash Ratio: |
N/A |
1.9 |
| Debt-to-Equity: |
N/A |
1.2 |
| Interest Coverage: |
N/A |
.4 |
| Technicals |
| Relative-Strength Index: |
N/A |
46.1 |
|
|
|
